ArticleScientific reports2025
Identification of key genes related to glutamine metabolism in diabetic nephropathy by machine learning methods.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- [Burden of Diabetic Kidney Disease at Global, Regional, and National Levels From 1990 to 2021].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic nephropathy (DN) is a critical microvascular complication of diabetes. Increasing evidence suggests that dysregulation of glutamine metabolism contributes to DN pathogenesis. This study aimed to explore alterations in glutamine metabolism-related genes (GMRGs) in DN. Nine differentially expressed GMRGs (DE-GMRGs) were identified by intersecting 103 GMRGs with 2,281 DEGs from the GSE142153 dataset comparing normal and DN groups. Notably, DE-GMRGs located on autosomes were significantly enriched in pathways related to glutamine metabolism and the metabolism of alanine, aspartate, and glutamate. The Least Absolute Shrinkage and Selection Operator (LASSO) and Support Vector Machine-Recursive Feature Elimination (SVM-RFE) methods were employed to pinpoint key genes, SLC7A5 and SLC25A12. SLC7A5 was found to be upregulated in DN, whereas SLC25A12 showed decreased expression. The diagnostic potential of these genes was further validated by assessing the area under the receiver operating characteristic (ROC) curve. Correlation analysis revealed strong associations between these key genes and clinical markers such as glomerular filtration rate (GFR), serum creatinine, and immune cells, including mast cells and effector memory CD8 T cells. Drug prediction and molecular docking analyses indicated that valproic acid might serve as an effective therapeutic agent targeting these genes. Glutamine metabolism-related genes SLC7A5 and SLC25A12 were identified as potential diagnostic and therapeutic targets for DN. These findings offer valuable clinical insights for the diagnosis and management of DN.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.